Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults -
- Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV -
- Initiation of Phase 2 Trial of IVX-A12 with topline interim results now expected by end 2023 -
- Closed $67.8 million registered direct offering of common stock; extended cash runway into 2H 2025 -
https://finance.yahoo.com/news/icosavax-reports-second-quarter-2023-200500421.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.